Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 10
2005 5
2006 5
2007 12
2008 6
2009 7
2010 14
2011 8
2012 13
2013 6
2014 11
2015 4
2016 11
2017 11
2018 6
2019 5
2020 13
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

143 results
Results by year
Filters applied: . Clear all
Page 1
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B. Grever MR, et al. Among authors: gozzetti a. Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30. Blood. 2017. PMID: 27903528 Free PMC article.
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
Mateos MV, Kumar S, Dimopoulos MA, González-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Geraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J. Mateos MV, et al. Among authors: gozzetti a. Blood Cancer J. 2020 Oct 16;10(10):102. doi: 10.1038/s41408-020-00366-3. Blood Cancer J. 2020. PMID: 33067414 Free PMC article.
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.
Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, Engelhardt M, Gay F, García Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum C, Kumar S, Stadtmauer EA, Einsele H, Beksac M, Weisel K, Anderson KC, Mateos MV, Moreau P, San-Miguel J, Munshi NC, Avet-Loiseau H. Chari A, et al. Among authors: gozzetti a. Blood. 2020 Dec 24;136(26):3033-3040. doi: 10.1182/blood.2020008150. Blood. 2020. PMID: 33367546 Free PMC article.
Daratumumab efficacy in extramedullary orbital myeloma.
Gozzetti A, Cerase A, Bocchia M. Gozzetti A, et al. Clin Case Rep. 2020 Oct 28;8(12):3652-3653. doi: 10.1002/ccr3.3458. eCollection 2020 Dec. Clin Case Rep. 2020. PMID: 33364021 Free PMC article.
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.
Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Durán MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pečeliūnas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbényi Z, Abadi U, Pedersen RS, Černelč P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M; EMMOS Investigators. Mohty M, et al. Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):e401-e419. doi: 10.1016/j.clml.2018.06.018. Epub 2018 Jun 25. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30030033 Free article.
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19.
Gozzetti A, Capochiani E, Bocchia M. Gozzetti A, et al. Leukemia. 2020 Oct;34(10):2815-2816. doi: 10.1038/s41375-020-01038-8. Epub 2020 Sep 2. Leukemia. 2020. PMID: 32879427 Free PMC article. No abstract available.
Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Gozzetti A, Candi V, Brambilla CZ, Papini G, Fabbri A, Bocchia M. Gozzetti A, et al. Anticancer Agents Med Chem. 2017;17(8):1040-1045. doi: 10.2174/1871520616666160928153342. Anticancer Agents Med Chem. 2017. PMID: 27697038 Review.
Commentary.
Gozzetti A. Gozzetti A. J Neurosci Rural Pract. 2013 Oct;4(4):448. J Neurosci Rural Pract. 2013. PMID: 24347955 Free PMC article. No abstract available.
Second Generation Proteasome Inhibitors in Multiple Myeloma.
Gozzetti A, Papini G, Candi V, Brambilla CZ, Sirianni S, Bocchia M. Gozzetti A, et al. Anticancer Agents Med Chem. 2017;17(7):920-926. doi: 10.2174/1871520616666160902101622. Anticancer Agents Med Chem. 2017. PMID: 27592543 Review.
143 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page